Specify a stock or a cryptocurrency in the search bar to get a summary
Synairgen plc
SNGSynairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. Address: Mailpoint 810, Southampton, United Kingdom, SO16 6YD
Analytics
WallStreet Target Price
618.06 GBXP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SNG
Dividend Analytics SNG
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SNG
Stock Valuation SNG
Financials SNG
Results | 2019 | Dynamics |